Dr. West on Lurbinectedin in SCLC

H. Jack West, MD
Published: Wednesday, Sep 20, 2017



H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses the emerging agent lurbinectedin in the small cell lung cancer (SCLC) landscape.

This agent is a marine-derived compound that does have activity in SCLC, West explains. Up until recently, however, lurbinectedin has only been studied in combination with doxorubicin. Recent findings at the 2017 ESMO Congress showed that lurbinectedin does have single-agent activity.

The ongoing, phase III ATLANTIS study is exploring the drug in relapsed SCLC where patients receive the combination of lurbinectedin/doxorubicin versus topetecan or the older combination of vincristine, cyclophosphamide, and doxorubicin (CAV), he adds. If these results are positive, it would be a novel regimen to add to the limited therapeutic landscape.
 


H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses the emerging agent lurbinectedin in the small cell lung cancer (SCLC) landscape.

This agent is a marine-derived compound that does have activity in SCLC, West explains. Up until recently, however, lurbinectedin has only been studied in combination with doxorubicin. Recent findings at the 2017 ESMO Congress showed that lurbinectedin does have single-agent activity.

The ongoing, phase III ATLANTIS study is exploring the drug in relapsed SCLC where patients receive the combination of lurbinectedin/doxorubicin versus topetecan or the older combination of vincristine, cyclophosphamide, and doxorubicin (CAV), he adds. If these results are positive, it would be a novel regimen to add to the limited therapeutic landscape.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x